

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equality issues were raised during the scoping process.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

N/A

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

N/A

- | |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338)

Issue date: May 2016

No.

Approved by Associate Director (name): Frances Sutcliffe

Date: 04/05/2016

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib (review of TA338)

Issue date: May 2016